Skip to main content
Beginner 6 min read

What Oligometastatic Cancer Means: Oligometastases Explained

Oligometastatic means a limited number of metastases. Some people with it are treated with local therapy aiming at long-term control or even cure.

NCI source:National Cancer Institute

Review status: AI-assisted, source checked. Not reviewed by a clinician. How we check pages

The short answer

Oligometastatic cancer means a small, limited number of metastases. Because the disease is confined, local treatments such as targeted radiation or surgery may be used with long-term control in mind.

  • Oligometastatic describes cancer that has spread, but only to a limited number of sites. It sits between localised disease and widespread metastatic disease.

  • There is no single agreed definition. Many studies use five or fewer metastases as a working cut-off, a threshold NCI notes was arbitrarily chosen.

  • The significance is that local treatments aimed at the metastases themselves, such as surgery or stereotactic body radiation, may be added to systemic therapy.

  • In colorectal cancer with liver-only metastases, roughly 20 percent of people are alive at ten years after surgical removal of the primary tumor and the metastases.

Choose how you want to read this

The whole article, with every detail and caution.

This page is for people with metastatic cancer, and those close to them, who want to understand the term "oligometastatic" and what it may mean for treatment.

A Middle Category That Many People Never Hear Named

Most people are given one of two pictures. Either the cancer is localized (still in one place), or the cancer has spread. Oligometastatic describes a state in between. It means cancer that has spread, but only to a small number of places.

The prefix oligo- simply means few. But the reason it matters is not about words. If the disease really is limited to a handful of sites, it may be possible to treat those sites directly. In some people that leads to long-term control or cure, not just to slowing things down.

Researchers quoted by the National Cancer Institute describe oligometastatic cancer as an in-between state, rather than treating all metastatic cancer as one group.

How Few Is Few

There is no single agreed definition. It is worth knowing that, rather than assuming a firm cut-off exists.

Many studies use five or fewer metastases as a working cut-off. NCI notes plainly that this number was arbitrarily decided upon. Other definitions may also limit how many organs are involved, or separate metastases found at diagnosis from those that appear later.

In practice the count is only part of the picture. Where the deposits sit matters. So does whether they can be reached safely, how quickly they appeared, and how the cancer has behaved on systemic treatment.

What Changes If the Label Applies

Standard treatment for metastatic cancer is systemic. That means drug therapy that travels through the whole body. In oligometastatic disease, a further option opens up: adding local treatment aimed at the metastases themselves.

  • Surgery to remove a metastasis. NCI describes this for colorectal cancer that has spread only to the liver.
  • Stereotactic body radiation therapy (SBRT/SABR), which sends a high, tightly focused dose to a small target over a few sessions.

The goal shifts. Instead of holding the disease in check with drugs, the aim may be to wipe out every visible site of cancer.

What the Evidence Shows

The clearest example is colorectal cancer that has spread only to the liver. When the primary tumor and the liver metastases are both removed by surgery, roughly 20 percent of people are alive at ten years. That is not slowing disease down. For those people it is cure.

The SABR-COMET trial went further. It randomly assigned people with a limited number of metastases from various cancers to standard treatment alone, or standard treatment plus SBRT to all metastatic sites. The people who received SBRT lived more than a year longer than the control group.

That result is genuinely encouraging. It is also genuinely provisional. The trial was small, with about 100 people. There were many more people with prostate cancer in the radiation group than in the control group. And there were three treatment-related deaths. Researchers involved have been careful to say that larger trials should report before practice changes across the board. SABR-COMET-3 and SABR-COMET-10, along with other studies, are running now.

Why This Gets Missed

Local treatment of metastases is not standard for every cancer type or every pattern of spread. It may need a radiation oncologist or surgeon and a medical oncologist to review a case together.

So it is fair to ask directly whether your disease could be called oligometastatic, and whether local treatment of your metastases has been considered.

Holding This Carefully

Two things are true at once. The oligometastatic idea has changed what is possible for some people with metastatic cancer, and it is a real source of hope that many patients are never told about. It also does not apply to everyone. The evidence is still maturing, and ablative treatment carries risks that depend on where the disease sits.

If you have a small number of metastases, three specific questions can help:

  • Does this apply to me?
  • What is the goal of treatment, in plain words?
  • Is there a clinical trial I would be eligible for?

Sources

A woman in headscarf stands in a clinic hallway near an MRI machine

Common questions

Is oligometastatic cancer curable?

For some people, yes, and that possibility is what makes the concept worth knowing about. NCI reports that about 20 percent of people with colorectal cancer whose primary tumor and liver-only metastases were removed by surgery lived at least 10 years. That is not the expected outcome for everyone, and durable control without cure may be a more realistic goal. Ask your team what outcome they are aiming for in your case, in plain terms.

How many metastases is too many?

There is no fixed number. Five or fewer is the most commonly used research cut-off, but NCI is explicit that this threshold was arbitrarily decided upon. Where the metastases are, whether they can be safely reached, how quickly they appeared, and how the cancer has behaved on systemic treatment all matter as much as the count.

What is SBRT or SABR?

Stereotactic body radiation therapy, also called stereotactic ablative radiotherapy, delivers precisely targeted radiation to a small area over a small number of sessions. It is designed to focus on a small tumor while limiting exposure of nearby tissue.

My oncologist has not mentioned this. Should I raise it?

It is a reasonable question to ask if you have a small number of metastases. Whether it applies depends on your cancer type, where the metastases are, how well systemic treatment is working and your general fitness. Asking whether local treatment of your metastases has been considered, and whether your case has been reviewed at a multidisciplinary tumor board, is a fair and specific question.

Is this treatment risky?

It carries real risk, and it is worth being clear-eyed about that. In SABR-COMET there were three treatment-related deaths, and researchers have emphasised that treating metastases directly is not free of harm. The decision weighs the possibility of longer survival against side effects that depend heavily on where the metastases sit.

Questions to ask your doctor

Being prepared helps you get the most out of your appointments. Save or print these questions.

Open my question list

Tap a question to save it to your list (kept on this device).

More words from this kind of report

Other guides in stage, grade & treatment response.

Talk to a person

Talk with a trained specialist or navigator

Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.

Free & Confidential

Talk to a trained cancer information specialist

Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.

Contact your oncology team

Locate after-hours contact numbers, portal messages, or urgent triage phone lines.

Find a patient navigator

Get one-on-one help with appointments, logistics, translation, and care coordination.

Find a genetic counselor

Discuss inherited mutation risk, family history, and genetic testing options.

Find an oncology social worker

Access emotional counseling, family support groups, and mental health resources.

Find a financial navigator

Locate copay assistance foundations, grant programs, and lodging/travel support.

Find a clinical-trial specialist

Search matching studies and speak with NCI trial information specialists.

Get urgent help

Fever of 100.4°F (38°C) or higher during chemo, severe pain, or trouble breathing: call your cancer care team right away, day or night. Call 911 for an emergency.

Prepared by Cancer Explained's AI-assisted editorial system

Written from National Cancer Institute material and compared with the source cited below.

Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.

Written by: Cancer ExplainedSources last checked: 2026-10-02 what this meansLast updated: 2026-08-10Next planned review: 2027-07-30

Review details and limits

Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes, and this is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.

Editorial status — Source checked. This page was written with AI assistance and then compared with the sources listed on it, looking for statements those sources do not back up. That check is not a sentence-by-sentence record and can miss errors. It is not a medical review, and it does not confirm the page is complete or right for your situation.

General education. Low-risk educational or organizational content. Medical facts are cited to authoritative sources.

Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.

Our editorial processHow we use AIReport an error

More on this topic

Words to know

Tap any term to see what it means.

Browse the full glossary →

How this page was created

Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes, and this is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.

Editorial status: Source checked — This page was written with AI assistance and then compared with the sources listed on it, looking for statements those sources do not back up. That check is not a sentence-by-sentence record and can miss errors. It is not a medical review, and it does not confirm the page is complete or right for your situation.

Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.

Read more about our editorial process, our use of AI, and our corrections policy.

Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.

After using this page, do you understand what to do next?

Anonymous — we only record the answer, never who gave it.